Can a core set of disease activity domains define response in systemic lupus erythematosus clinical trials? An analysis of two Phase 3 randomised controlled trials of belimumab

Systemic lupus erythematosus (SLE) is a disease where the immune system mistakenly attacks the body’s own tissues, causing inflammation and damage. It can affect any part of the body, such as the skin, joints, kidneys, and heart. The symptoms and severity of the disease can vary greatly from one person to another, which makes it difficult to measure disease activity and track how well treatments are working. This is a significant challenge in recent clinical trials for lupus, as it is hard to determine the effectiveness of new treatments due to the variety of symptoms.

Currently, the tools used in clinical trials try to measure almost all of the possible symptoms that can occur in lupus. However, many of these symptoms are rare, not well understood, or hard to measure accurately, which makes it difficult to assess how well a treatment is working. This can lead to confusing results.

We believe that focusing on a smaller, more manageable group of the most common and measurable symptoms of lupus—referred to as a “core set”—might provide a more effective way to measure disease activity and treatment response. Our research aims to test this idea by looking at data from three previous clinical trials of a drug called belimumab. We want to see if we can identify which patients responded well to treatment by focusing on this smaller set of disease features.

If successful, this approach could simplify the way clinical trials are conducted, making it easier to evaluate how well new treatments work. It would also help focus on the most important aspects of lupus that affect patients' daily lives, leading to more accurate and meaningful results for those who participate in future clinical trials.